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Abstract
Background: A substantial body of evidence indicates that reduced plasma adiponectin levels may
be key in the development of insulin resistance, type 2 diabetes and the metabolic syndrome.
Glucocorticoids decrease the levels of adiponectin in animals and humans. Cortisone is
transformed to its active form cortisol, via 11β-hydroxysteroid dehydrogenase (HSD) type 1. This
study sought to ascertain if inhibition of 11β HSD1 with a new selective inhibitor, BVT116429,
affects the concentrations of circulating adiponectin with concomitant effects on glucose
homeostasis in diabetic mice.
Results: KKAy mice were treated with BVT116429 (3, 10, 30 mg/kg), rosiglitazone (5 mg/kg) or
vehicle once daily for ten days. Plasma adiponectin levels rose in mice treated with BVT116429 and
this was found to be both the hexameric and the high molecular weight multimeric forms of
adiponectin. Seven days of treatment with the 11β HSD1-inhibitor BVT116429 decreased basal
insulin levels but no changes in glucose tolerance were seen. After ten days of treatment, fasting
blood glucose level was decreased by BVT116429 comparable to the effects of rosiglitazone.
Another 11β HSD1 inhibitor, BVT2733, improved HbA1c but had no effect on adiponectin.
Conclusion: Inhibition of 11β HSD1 can be expected to be beneficial for treating the pathology
of type 2 diabetes mellitus. The differences seen in adiponectin between BVT116429 and BVT2733
could be explained by different pharmacodynamics exerted by the compounds in different tissues
in the body. Increases in adiponectin concentrations may be an integral component in the
mechanism of action of this new11β HSD1 inhibitor and may be a useful marker of efficacy during
the clinical development of 11β HSD1 inhibitor compounds.
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Background
Type 2 diabetes and Cushing's syndrome have similar
phenotypes, including visceral obesity, dyslipidemia,
hyperglycemia and insulin resistance [1]. In the case of
Cushing's syndrome, the patients have elevated circulat-
ing glucocorticoids whereas patients with type 2 diabetes
have normal circulating levels but higher intracellular lev-
els [2]. The concentration of active glucocorticoids (corti-
sol, corticosterone) formed at the cellular level is
regulated by the degree of reductase activity of the 11β-
hydroxysteroid dehydrogenase (HSD) type 1 enzyme [3].
Glucocorticoids have been shown to decrease the levels of
adiponectin in animal models [4,5] and in humans [6].
Adiponectin is a hormone secreted exclusively from adi-
pose tissue [7], the concentrations of which are positively
correlated with a favorable metabolic phenotype in
humans [8]. It circulates in serum as a basic trimer, a hex-
amer, and larger multimeric structures [9]. The full-length
protein influences hepatic gluconeogenesis whilst the
globular domain of adiponectin stimulates β-oxidation in
muscle. These effects are mediated by the AdipoR2 (liver)
and AdipoR1 (muscle) receptors respectively [10].
Recently it was shown that the APPL1 adaptor protein
binds to the intracellular domain of adiponectin receptors
and confers some of adiponectin's actions [11], and thus
may be an important mediator of adiponectin-dependent
insulin sensitization in skeletal muscle. The mRNA
expression of adiponectin is reduced in adipose tissue in
obese mice and humans [12] although the picture differs
somewhat depending on fat depot. Adiponectin is not
only decreased in obese individuals but also in type 2 dia-
betic patients [7] and a low level is a risk factor for devel-
oping this disease [13]. Physiological doses of
adiponectin improve insulin sensitivity in db/db and
KKAy mice, two mouse models of type 2 diabetes, partly
by decreasing triglycerides (TG) in liver and muscle tissue
[14]. Treatment with thiazolidinediones increases the
expression and secretion of adiponectin in both rodents
and humans [15,16], indicating that changes in this adi-
pokine may be integral to the therapeutic effects of thiazo-
lidinediones [17,18].
Transgenic mice overexpressing 11β HSD1-selectively in
adipose tissue develop type 2 diabetes and visceral obesity
[4], in contrast to the 11β HSD1 knockout mouse, which
displays a favorable phenotype with normoglycemia and
normal weight [5,19,20]. This animal resists diet-induced
obesity, has improved glucose and insulin tolerance and
demonstrates favorable changes in cytokine expression,
including a doubling in adiponectin. Another transgenic
mouse overexpressing HSD type 2 in adipose tissue, and
thereby inhibiting corticosterone exposure intracellularly,
also had higher expression of adiponectin than its wild
type counterparts when fed a high fat diet [21]. Various
inhibitors of 11β HSD1 have been disclosed, with multi-
ple favourable effects on the metabolic phenotype. In
addition to increased insulin sensitivity and glucose toler-
ance [22-26], anti-obesity effects such as reduced food
intake, body weight gain and reduced percentage body fat
have been reported [24,25]. Furthermore, atherosclerotic
plaque lesions in apoE knockout mice were improved
after treatment with 11β HSD1 inhibitors [25]. However,
despite favourable effects on the insulin-sensitising adi-
pokine adiponectin in genetic models of 11β HSD1 inhi-
bition and corticosterone reduction, no such analysis has
been reported in pharmacological models. Substance
BVT116429 inhibited11β HSD1 in adipose tissue. It has
good bioavailability (75% is free from plasma protein
binding) and low clearance, resulting in high Cmax values
[27]. When tested in C57Bl6 mice, the compound dis-
played excellent pharmacodynamics in adipose tissue,
inhibiting 11β HSD1 activity by 90%, 2 and 6 hours after
dosing (30 mg/kg) [27]. The aim of this study was to
investigate if inhibition of 11β HSD1 in adipocytes with
the specific inhibitor BVT116429 affects the concentra-
tions of adiponectin with concomitant impact on glucose
homeostasis in diabetic mice. We compared the effects
with BVT2733 [23], another 11β HSD1 inhibitor shown
to exert its effects through alteration of glucose handling
in the liver.
Results
Potency and pharmacodynamic activity of 11β HSD1 
inhibitor BVT116429
BVT116429 ((S)-2-((S)-1-(2-fluorophenyl)ethylamino)-
5-methyl-5-(trifluoromethyl)thiazol-4(5H)-one (Fig. 1)
is a potent reversible competitive inhibitor of human and
mouse 11β HSD1 with > 250 fold selectivity over human
11β HSD2. Inhibitory constants derived from in vitro
inhibition assays using purified recombinant mouse and
human 11β HSD1 were 36 and 29 nM, respectively (aver-
age from repeated assays performed in triplicate). Repre-
sentative data for human the enzyme is shown in figure 2.
BVT116429 had no significant effect on a panel of 80
unrelated proteins and ion channels (data not shown). To
determine the effect of BVT116429 in cells, human pri-
mary adipose cells were treated with increasing concentra-
tions of compound and the ability of the cells to convert
cortisone to cortisol was assessed using a cortisol ELISA
assay. Repeated assays showed that BVT116429 inhibited
intracellular 11β HSD1 with an IC50 of 26 nM (Fig. 3). To
understand the degree of 11β HSD1 inhibition in liver
from mice dosed with BVT116429 at 30 mg/kg, the liver
was excised 2 h post last dose, minced and exposed to cor-
tisone ex vivo for 30 minutes. Data showed that the com-
pound inhibits conversion of cortisone to cortisol by 11β
HSD1 in liver such that two hours post-dosing, liver 11β
HSD1 activity was reduced by 35% (2.12 ± 0.40 ng corti-
sol formed/mg/30 min in vehicle and 1.36 ± 0.25 ng cor-BMC Pharmacology 2008, 8:3 http://www.biomedcentral.com/1471-2210/8/3
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tisol formed/mg/30 min in BVT116429). This contrast
with the compounds greater effects in adipose tissue (90%
6 h post dosing) [27]. Thus, BVT116429 displays signifi-
cant inhibitory activity against the enzyme in key target
organs after oral dosing in C57/Bl6J mice with especially
high activity in adipose tissue.
Effect of BVT116429 treatment on plasma glucose
To test the effects of BVT116429 on the diabetic pheno-
type of KKAy mice, male mice were treated with com-
pound for 10 days as described in the Methods section.
Fasting glucose was reduced in animals treated with 30
mg/kg BVT116429, an effect that was comparable to that
of rosiglitazone (Fig. 4).
Effects of BVT116429 on plasma glucose in KKAymice Figure 4
Effects of BVT116429 on plasma glucose in KKAym-
ice. The effect after 10-days treatment with vehicle (white 
circles), BVT116429 3 mg/kg (black circles), BVT116429 10 
mg/kg (white squares), BVT116429 30 mg/kg (black squares) 
or rosiglitazone (white triangles) on plasma glucose. *p < 
0.05 and **p < 0.01 when compared with vehicle.
Inhibition curve for human 11β HSD1 by increasing concen- trations of BVT116429 Figure 2
Inhibition curve for human 11β HSD1 by increasing 
concentrations of BVT116429. Error bars are standard 
deviations of triplicate determinations. The solid line is a fit 
of the data to the equation y = Range/(1+(x/IC50)s) where 
range is the uninhibited value and s the slope factor.
Structure of BVT116429 Figure 1
Structure of BVT116429.
Inhibition curve for production of cortisol from cortisone by  primary human adipocytes Figure 3
Inhibition curve for production of cortisol from corti-
sone by primary human adipocytes. Terminally differen-
tiated adipocytes were incubated in the presence of 
cortisone and increasing concentrations of BVT116429 and 
cortisol concentrations determined from the cell superna-
tants. Data are means of triplicate determinations with stand-
ard deviations indicated. The solid line is a fit of the data to 
the same equation as in Fig 2.BMC Pharmacology 2008, 8:3 http://www.biomedcentral.com/1471-2210/8/3
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Effect of BVT116429 treatment on adiponectin in vivo and 
in vitro
Different transgenic mouse models with altered 11β
HSD1 activity or glucocorticoid concentrations demon-
strate elevated adiponectin concentrations. For this rea-
son, and considering the apparently greater effects of
BVT116429 on 11β HSD1 activity in adipose tissue, we
measured adiponectin in KKAy  mice treated with
BVT116429. Total adiponectin levels were elevated in
KKAy mice after treatment with both BVT116429 (30 mg/
kg) and rosiglitazone compared with control (Fig. 5). In
view of recent findings that the distribution of different
adiponectin complexes is critical in determining insulin
sensitivity [9], we decided to investigate the complex com-
position of adiponectin in serum from the KKAy mice. The
most prominent adiponectin complex in KKAy mice was
the hexamer (MMW). Both the hexameric and the high
molecular weight (HMW) multimeric forms were
increased after treatment with BVT116429 (Fig. 6) and
rosiglitazone (data not shown). In order to understand
the mechanistic interplay between 11β HSD1 inhibition
and a concomitant increase of adiponectin levels better,
we studied human primary adipocytes in culture. Termi-
nally differentiated human adipocytes were treated with
BVT116429 for 48 hours in the presence of cortisone. Adi-
ponectin concentrations released into the culture medium
increased by 1.5-fold, from 13.6 ng/ml in the absence of
compound to 20.1 ng/ml in its presence (mean values
from pooled samples of sextuplicate determinations).
Thus, inhibition of 11β HSD1 activity in adipocytes is
able to increase adiponectin production, suggesting that
the effect seen in intact mice is a direct one on the adipose
mass.
Effect of BVT116429 on glucose tolerance and insulin 
sensitivity
Glucose excursions after a glucose challenge in oGTT were
not altered by either rosiglitazone or BVT116429, indicat-
ing no effect on glucose tolerance in these animals (Fig.
7A). The insulin curve is shown in figure 7B. Basal plasma
Proportion of high and medium molecular weight adiponec- tin in KKAymice Figure 6
Proportion of high and medium molecular weight 
adiponectin in KKAy mice. Velocity sedimentation analy-
sis of serum from KKAy mice treated with the indicated 
amounts of compound BVT116429 or vehicle was per-
formed. This is a representative immunoblot showing the 
changes of the different adiponectin forms. Several independ-
ent analyses were performed giving similar results. The two 
main adiponectin complexes, HMW and MMW bands, are 
indicated by arrows and molecular mass markers are shown.
Effects on plasma adiponectin in KKAymice Figure 5
Effects on plasma adiponectin in KKAy mice. The effect 
after 10-days treatment with vehicle (white circles), 
BVT116429 3 mg/kg (black circles), BVT116429 10 mg/kg 
(white squares), BVT116429 30 mg/kg (black squares) or ros-
iglitazone (white triangles) on plasma adiponectin. * p < 0.05, 
** p < 0.01 when compared with vehicle.BMC Pharmacology 2008, 8:3 http://www.biomedcentral.com/1471-2210/8/3
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insulin level was decreased for both rosiglitazone (2.85 ±
0.29 mg/ml, p < 0.01) and BVT116429 (30 mg/kg, 3.63 ±
0.29 ng/ml, p < 0.01) compared with vehicle (6.07 ± 0.55
ng/ml) indicating increased insulin sensitivity already
after seven days of treatment.
To examine more specifically the effects of BVT116429 on
insulin sensitivity, an insulin tolerance test was performed
in male KKAy mice. Animals were treated with BVT116429
for seven days prior to the test. After an overnight fast, ani-
mals were given an intraperitoneal bolus of insulin (1 U/
kg) and blood glucose was followed for two hours. When
fitted to a single exponential equation, the glucose elimi-
nation rate constant (min-1 *1000) were 2.0 ± 0.6 (vehi-
cle), 2.5 ± 1.0 (3 mg/kg BVT116429), 4.2 ± 0.9 (10 mg/kg
BVT116429), 3.5 ± 0.7 (30 mg/kg BVT116429) and 5.0 ±
0.9 (5 mg/kg rosiglitazone). The apparent increased elim-
ination rate constant did not however show statistical sig-
nificance (p = 0.07, F-test).
Euglycemic hyperinsulinemic clamp
To examine the effects of BVT116429 at the level of the
liver more specifically, a euglycemic hyperinsulinemic
clamp was performed in male KKAy mice. Animals were
treated once daily with 30 mg/kg BVT116429 or vehicle
for eight days, starting three days after surgery to implant
a catheter in the right jugular vein. After a 6 hour fast, the
clamp was performed as described in the Methods section.
BVT116429 had no effect on hepatic glucose production.
Basal endogenous glucose production was 33.1 ± 9.5 (mg/
kg.min) and 36.3 ± 12.8 (mg/kg.min), and after insulin
infusion 23.7 ± 6.0 (mg/kg.min) and 20.9 ± 7.5 (mg/
kg.min), for vehicle and BVT116429 respectively.
Effect on food intake, body weight and leptin
There were no differences in food intake between different
treatment groups over the 10 day treatment period (Table
1). The group of rosiglitazone treated animals was the
only group that gained weight during the study (Table 1).
To determine the proportion of fat in the animals, fat pads
were dissected and weighed and normalized to the whole
body weight (fat pad/BW × 100, Table 1). The data
showed no significant changes in fat mass after treatment
with BVT116429 or rosiglitazone. In a separate experi-
ment, body composition was determined by dual energy
X-ray absorptimetry to take total body fat into account
instead of epididymal fat alone. These results showed that
there were no significant change in total body adiposity
after treatment with BVT116429 compared to vehicle
(vehicle, 36.2 ± 2.5% fat; 3 mg/kg, 38.2 ± 3.1%, 10 mg/kg,
36.9 ± 3.1 and 30 mg/kg, 37.6 ± 2.4%, n = 8 per group).
By contrast, animals treated with rosiglitazone showed
increased adiposity to 40.3 ± 3.4% (p < 0.01 versus vehi-
cle). As expected, the leptin level was elevated for the ros-
iglitazone group compared with the vehicle group (Table
1). The highest dose group of BVT116429 (30 mg/kg) had
higher leptin levels than the control group despite no sig-
nificant changes in total body adiposity.
Effect on plasma and liver lipids
Total plasma cholesterol was elevated in animals treated
with rosiglitazone compared with the control group, and
this was accompanied by elevated plasma HDL-choles-
terol and lowered cholesterol in the liver (Table 1), but no
effects were seen with BVT116429.
Glucose tolerance test after treatment with BVT116429 in KKAy mice Figure 7
Glucose tolerance test after treatment with BVT116429 in KKAy mice. The effect of vehicle (white circles), 
BVT116429 30 mg/kg (black squares) or rosiglitazone (white triangles) on glucose tolerance test. Plasma glucose (A) and insulin 
(B) are shown in response to 2 g/kg of glucose. Data are expressed as means ± SEM.BMC Pharmacology 2008, 8:3 http://www.biomedcentral.com/1471-2210/8/3
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Effects of the 11βHSD1 inhibitor BVT2733 on adiponectin 
concentrations
To assess the effects of a second 11β HSD1 inhibitor,
BVT2733, on plasma adiponectin concentrations, male
KKAy mice were treated with three different doses of the
compound twice daily for 8 days, as described in the
Methods section. Analysis of the plasma samples showed
that BVT2733 had no significant effect on adiponectin
concentrations (Fig. 8A). By contrast, rosiglitazone again
caused significant increases in plasma adiponectin. Anal-
ysis of plasma HbA1c concentrations showed that the
treatment with BVT2733 reduced HbA1c significantly at
30 and 300 mg/kg, confirming its expected anti-hypergly-
cemic effects (Fig. 8B).
Discussion
Patients with type 2 diabetes have high intracellular levels
of glucocorticoids [2]. The level is regulated by 11β HSD1
and inhibition of this enzyme in the adipose tissue is one
possible novel way of treating type 2 diabetes. In contrast
to their wild type siblings, 11β HSD1 -/- mice lack mRNA
for 11β HSD1 and cannot convert 11-dehydrocorticoster-
one to active corticosterone [20]. When these mice were
fed a high fat diet, blood glucose concentrations were
lower compared with wild type animals. Indeed, 11β
Effects of BVT2733 on (A) adiponectin and (B) glycosylated hemoglobin in male KKAymice Figure 8
Effects of BVT2733 on (A) adiponectin and (B) glycosylated hemoglobin in male KKAy mice. Animals were 
treated with vehicle (white circles), BVT2733 30 mg/kg (black circles), BVT2733 100 mg/kg (white squares), BVT2733 (black 
squares) or 5 mg/kg rosiglitazone (white triangles) for 8 days and plasma adiponectin and HbA1c were measured. * p < 0.05, ** 
p < 0.01, *** p < 0.001 versus vehicle, n = 9 per group.
Table 1: Effect of 10-day treatment on various metabolic parameters
Vehicle 3 mg/kg 10 mg/kg 30 mg/kg Rosiglitazone
Food Intake (g) 47.8 ± 2.2 48.6 ± 2.3 51.1 ± 1.9 42.9 ± 1.3 50.6 ± 1.2
Body Weight (g) 39.9 ± 0.7 42.9 ± 1.2 41.2 ± 1.0 43.5 ± 1.3 45.0 ± 1.0**
Body Weight as percent of initial (%) 96.4 ± 1.0 98.0 ± 0.7 98.1 ± 0.5 100.4 ± 0.1 107.3 ± 1.2**
Initial body weight (g) 41.4 ± 0.8 43.8 ± 1.2 41.9 ± 0.8 43.3 ± 1.3 41.9 ± 0.68
Fat Pad weight (g) 1.60 ± 0.07 1.72 ± 0.05 1.55 ± 0.04 1.50 ± 0.07 1.68 ± 0.07
Fat pad/body weight ×100 4.02 ± 0.18 4.03 ± 0.19 3.77 ± 0.14 3.54 ± 0.23 3.74 ± 0.16
Leptin (ng/ml) 57.2 ± 0.7 68.6 ± 4.5 59.4 ± 2.3 73.6 ± 3.1* 83.6 ± 2.9***
Insulin (ng/ml) 20.8 ± 5.2 23.6 ± 4.0 13.6 ± 4.6 17.7 ± 8.4 11.8 ± 2.5
Triglycerides (ng/ml) 1.90 ± 0.18 2.29 ± 0.13 2.6 ± 0.46 3.03 ± 0.30 2.3 ± 0.29
Liver triglycerides (mg/g liver) 14.7 ± 1.0 20.4 ± 3.0 15.2 ± 1.0 18.5 ± 1.4 20.9 ± 2.0
Total cholesterol (mM) 4.0 ± 0.2 3.9 ± 0.1 4.0 ± 0.1 4.1 ± 0.2 5.1 ± 0.3**
HDL cholesterol (mM) 3.1 ± 0.2 3.0 ± 0.1 3.1 ± 0.1 3.2 ± 1.3 4.1 ± 0.2**
Liver cholesterol (mg/g liver) 4.0 ± 0.2 3.8 ± 0.2 4.3 ± 0.2 3.6 ± 0.1 3.2 ± 0.1*
Data are mean ± SEM, n = 8 per group. *p < 0.05, **p < 0.01 and ***p < 0.001 significantly different from vehicleBMC Pharmacology 2008, 8:3 http://www.biomedcentral.com/1471-2210/8/3
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HSD1 -/- mice fed a high fat diet do not become hyperg-
lycemic. Morton et al studied 11β HSD1 -/- mice with a
focus on lipid metabolism and reported lower plasma
triglyceride levels compared with wild type animals [19].
The same group studied mRNA expression of leptin and
adiponectin in epididymal fat of 11β HSD1 -/- mice and
saw decreased leptin and increased adiponectin [5]. Ker-
shaw et al created a transgenic model in which human 11β
HSD2 was expressed under the control of the murine adi-
pocyte fatty acid binding protein promoter and thereby
increased 11β HSD2 expression and activity exclusively in
adipose tissue, resulting in a phenotype with less gluco-
corticoid in adipose tissue due to enhanced inactivation
of corticosterone. This model displayed increased expres-
sion of adiponectin in subcutaneous adipose tissue, when
fed a high fat diet compared with wild type [21]. This is in
accordance with the report of Masuzaki et al which
describes transgenic mice overexpressing 11β HSD1 in
adipose tissue with decreased adiponectin expression in
mesenteric fat [4]. Mesenteric fat was increased nearly four
times in this animal and expression of mRNA of adi-
ponectin was decreased to 42% compared to non-trans-
genic mice. Transgenic mice also had reduced glucose
tolerance and insulin sensitivity, measured by intraperito-
neal glucose tolerance tests and insulin tolerance tests,
compared to non-transgenic mice.
Thus these three animal models implicate an association
between glucocorticoid dynamics in adipose tissue and
adiponectin expression. In the present study, we show
that treatment with the specific 11β HSD1 inhibitor
BVT116429 (30 mg/kg) increases adiponectin concentra-
tions, both in adipocytes and, quantitatively and qualita-
tively, in serum. This is in accordance with other studies
where glucocorticoid is reported to inhibit both expres-
sion and secretion of adiponectin [6,28]. Adiponectin is
an activator of AMP activated protein kinase (AMPK)
which is proposed to be a metabolic master switch [29].
Activation of AMPK is supposed to lead to improved glu-
cose and fat metabolism including increased glucose
uptake in muscle, increased insulin sensitivity, increased
FFA uptake and oxidation and repressed lipogenesis
[30,31]. Interestingly some of these ameliorations are
achieved by treatment with BVT116429. In this study we
show that treatment with the specific 11β HSD1 inhibitor
BVT116429 (30 mg/kg) improves the glucose homeosta-
sis in diabetic KKAy mice. Fasting blood glucose was low-
ered by approximately 25% (Fig. 4) after ten days and
plasma insulin was reduced already after seven days of
treatment. Unfortunately the ITT did not show any signif-
icant differences in insulin sensitivity between the groups,
probably due to a combination of groups of too few ani-
mals in which insulin resistance varies substantially, and
a varied response to the experimental dose of insulin. 11β
HSD1 -/- mice have higher expression of uncoupling pro-
tein 2 (UCP-2) when fed high fat diet and this might be
due to the elevated expression in adiponectin [5]. Similar
metabolic modifications were shown with another 11β
HSD inhibitor, compound 544. Fasting serum glucose
was lowered by 15% and insulin levels were normalised
in diet induced obese mice after 11 days treatment [25].
The same group also reported decreased food intake and
decreased body weight gain.
Adiponectin is an important link between type 2 diabetes
and vascular disease[32,33]. Kumada et al showed in their
study in men that hypoadiponectinemia was associated
with coronary artery disease prevalence even after adjust-
ment for risk factors such as type 2 diabetes and body
mass index [34]. Adiponectin suppresses atherogenesis by
inhibiting adherence of monocytes, reducing their phago-
cytic activity and suppressing accumulation of lipopro-
teins in the vascular wall [35,36]. Hermanowski-Vosatka
et al [25] showed that inhibition with compound 544,
another 11β HSD inhibitor, slowed plaque progression in
a mouse model of atherosclerosis. We suggest that the
beneficial results regarding atherosclerosis may be due, at
least in part, to increased adiponectin. This study did not
report on concentrations of adiponectin in 544-treated
animals but we hypothesize that prolonged treatment
with BVT116429 will demonstrate similar effects due to
elevations in circulating adiponectin.
Our earlier 11β HSD1 inhibitor, BVT2733, has been
shown to exert significant effects on feeding behavior and
energy balance as well as glucose homeostasis in various
animal models of glucose intolerance and type 2 diabetes
[22-24]. Thus, the compound has shown strong effects in
the liver and possibly in the brain. Our analysis here
shows that BVT2733 has no effect on plasma adiponectin
concentrations, whilst BVT116429 has no effects on the
hepatic glucose production. These data indicate therefore
that whilst inhibition of 11β HSD1 can be expected to be
beneficial for treating the pathology of type 2 diabetes
mellitus, all inhibitors are not the same, and different
mechanistic effects can be expected with different com-
pounds. The differences likely lie in the subtly different
pharmacodynamics exerted by the compounds in differ-
ent tissues in the body. Thus BVT2733, which has strong
effects in the liver, likely regulates glucose homeostasis in
this organ, whilst BVT116429 has less effect in the liver
but upregulates the major insulin sensitizing adipokine
adiponectin, due to its greater effects in the adipose tissue.
Conclusion
In our study we have treated an animal model of type 2
diabetes with an 11β HSD1 inhibitor BVT116429 for up
to ten days and obtained several ameliorations of the dia-
betic phenotype, specifically lowered plasma glucose,
which is the most important clinical chemistry parameterBMC Pharmacology 2008, 8:3 http://www.biomedcentral.com/1471-2210/8/3
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to improve. Ten days is a relatively short treatment time
and a longer treatment could possibly lead to further
improvements such as improved dyslipidemia. Increases
in adiponectin concentrations may be an integral compo-
nent in the mechanism of action of 11β HSD1 inhibitors
which are active in the adipose tissue and may be a useful
marker of efficacy during the clinical development of
inhibitory compounds. This approach to the treatment of
type 2 diabetes might also reduce the risk of cardiovascu-
lar disease.
Methods
Animals
Male mice, KK-Ay (KKAy), from Charles River (Tokyo,
Japan) were given a high fat diet (D12266B, 32.5% fat,
Research Diets, NJ, USA) and water ad libitum. Animals
were kept in individual cages under a 12-h light/12-h dark
cycle, at 22 ± 1°C and 50% humidity. KKAy mice were ran-
domized into groups. One set of animals were adminis-
tered 11β HSD-inhibitor BVT116429 (3, 10 or 30 mg/kg),
or rosiglitazone (5 mg/kg) or vehicle by oral gavage (p.o.)
once daily at 1700 for 10 days. The other set of animals
were administered 11β HSD-inhibitor BVT2733 (30, 100
or 300 mg/kg), rosiglitazone (5 mg/kg) or vehicle by oral
gavage twice daily at 0700 and 1700 for eight days. Body
weight and food intake were monitored at the beginning
and at the end of the study. Body composition was ana-
lyzed by dual energy X-ray absorptimetry using a Lunar
Piximus densitometer. Terminal blood samples for
plasma analysis were taken after four hours of fasting at
1200 from the orbital sinus or via heart puncture in anaes-
thetized animals prior to euthanasia. The procedures
involving animals were in conformity with national and
international laws for the care and use of laboratory ani-
mals and were approved by the local animal ethical com-
mittee.
Oral glucose tolerance test (oGTT)
An oral glucose tolerance test was performed after an over-
night fast and two hours post-dosing on day seven of the
10-day experiment. Mice were given an oral dose of glu-
cose (2 g/kg; 200 mg/ml stock solution, Fresenius Kabi,
Uppsala, Sweden) and blood samples (tail cut, 25 µl) for
glucose (Accu-check, Roche, USA) and insulin (ELISA,
Mercodia, Uppsala, Sweden) were taken immediately
before the glucose load and 0, 15, 30, 60 and 120 min
after the glucose load.
Insulin tolerance test (ITT)
An insulin tolerance test was performed after a four hour
fast on day seven. Two hours after the daily dose of sub-
stance or vehicle, mice were given an intraperitoneal dose
of insulin (1 U/kg) and blood samples (tail cut, 5 µl) for
analyses of glucose (Accu-check, Roch, USA) were taken
after 0, 15, 30 60 and 120 min. For data analysis, glucose
concentrations were normalized to the concentration at
time zero and the rate of glucose elimination was calcu-
lated by fitting the data to a single exponential equation
(y = yoe-kt).
Euglycemic hyperinsulinemic clamp
Catheters were placed into the right jugular vein of male
KKAy  mice under anesthesia, and the animals were
allowed to recover for three days. After dosing with vehicle
or BVT116429 (30 mg/kg, p.o.) once daily for eight days,
animals were fasted for 6 hours. At the start of the clamp
experiment, all animals were infused with radiolabelled
glucose tracer (2.5 µCi/kg/min) and 70 minutes later,
insulin infusion was started at a rate of 12.5 mU/kg/min.
Blood glucose concentrations were monitored thereafter
and glucose was infused from a 30% solution as required
to maintain euglycemia. The experiment was terminated
after 160 minutes (90 minutes after insulin infusion was
commenced) and animals were euthanized. Data from
animals were included in the final analysis if there was no
more than 20% variation in basal and clamped glucose
levels, if there was at least a two-fold increase in blood
insulin concentrations upon insulin infusion, if there was
a specific activity of tracer glucose of at least 40000 cpm
per mg glucose in whole blood and if the catheter was
shown to be correctly inserted when the experiment was
terminated. Glucose disposal rate (GDR) was calculated
as (cpm/min) infused/(cpm/mg glucose in blood). Under
basal conditions prior to clamp, endogenous glucose pro-
duction (EGP) equals GDR. Under clamped conditions,
EGP was calculated as the difference between GDR and
glucose infusion rate (GIR).
Clinical chemistry
Blood samples were taken from anesthetized (Forene,
Abbot, Chicago, USA) mice via heart puncture or orbital
plexus, after a four hour fast on the final day. Samples
were kept on ice for 30 min before centrifugation at 2000–
3000 g for 10 min and subsequently stored in tubes at -
70°C until analysis. Glucose concentrations were ana-
lyzed with a UV method (Hitachi 912 Multianalyzer,
Roche Diagnostics, Switzerland). HbA1c, cholesterols,
triglycerides and free fatty acids were analyzed with an
enzymatic colorimetric method (Hitachi 912 Multiana-
lyzer, Roche Diagnostics, Switzerland). Serum adiponec-
tin and leptin were analyzed with radioimmuno assays
(Linco Research, St.Louis, MO, USA). Serum insulin was
analyzed using an enzyme-linked immunoassay (ELISA,
Mercodia, Uppsala, Sweden).
Tissues
The epididymus fat pad and liver were dissected, weights
were measured and tissue samples were snap frozen in liq-
uid nitrogen and stored at -70°C. Lipid extracts were pre-
pared by homogenizing frozen liver inBMC Pharmacology 2008, 8:3 http://www.biomedcentral.com/1471-2210/8/3
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Heptan:Isopropanol 3:2, Tween 1%. (1:10) and then ana-
lyzed with an enzymatic colorimetric test (Roche Diag-
nostic, Switzerland).
11β-HSD1 ex vivo Assay
DMEM (GIBCO BRL, 11965-092) media (37°C) was sup-
plemented with NADPH (Sigma, Cat# N1630) and corti-
sone (Sigma, Cat# C2755) to a final concentration of 100
µM and 1µM, respectively. 500 µl supplemented media
was dispensed to each well of a 24-well plate (Falcon, BD,
Cat# 353047). Frozen tissue was dissected into 30–40 mg
aliquots (weights recorded) and directly placed in the pre-
warmed media. Plates were incubated at 37°C for 3 hours
with substrate, and media subsequently collected (with-
out the tissue pieces) by transferring the supernatant to a
fresh 24-well plate (samples stored at -80°C until ready
for assay). Cortisol ELISA (Correlate-EIA kit, Assay
Designs Inc. Cat# 901-071) was performed as suggested
by the manufacturer with appropriate sample dilution
(usually 1:10 for mouse adipose tissue).
Velocity sedimentation of serum samples
5–40% sucrose gradients in 10 mM HEPES, pH 8.0, 125
mM NaCl were poured stepwise in 2 ml thin walled ultra-
centrifuge tubes (Becton-Dickinson) and allowed to
equilibrate overnight at 4°C. Following layering of the
sample on top (diluted 1:10 with 10 mM HEPES, pH 8.0,
125 mM NaCl), gradients were spun at 55 000 rpm for 4
hours at 4°C in a Beckman Optima XL-80K ultracentri-
fuge (SW55TI). 200 µl gradient fractions were sequentially
retrieved and analyzed by Western blot.
Immunoblotting
Proteins were separated by SDS-PAGE (non-reducing,
non-heat denaturing) and subsequently transferred to
PVDF-membranes (BioRad). Membranes were blocked
with 5% non-fat dry milk in TBST (Tris-buffered saline,
0.1% Tween20). As primary antibody, a rabbit polyclonal
antibody against adipose-denied complement-related
protein (Acrp30) was used (Santa Cruz #sc-17044-R). As
secondary antibody, a horseradish peroxidase (HRP)-con-
jugated goat anti-rabbit antibody was used (Upstate #12-
348). Blots were visualized using chemiluminiscense,
(enhanced chemiluminiscense (ECL) Plus detection kit,
GE Healthcare).
Adiponectin analyses in human primary adipocytes
Pre-adipocytes (Body mass index <25) were purchased
from ZenBio (SP-F-1). Culture medium (PM-1), differen-
tiation medium (DM-2) and adipocyte medium (AM-1)
were also from ZenBio. One ampoule of human primary
pre-adipocytes was thawed in a 37°C water bath and sub-
sequently suspended in 10 ml culture medium. 30 µl of
the cell suspension was transferred to an Eppendorf tube
and 15 µl Trypan blue was added. Cells were counted and
the viability was calculated. The remaining cell suspen-
sion was diluted to a final volume of 78 ml culture
medium. Cell suspension aliquots, containing 8–9000
cells, were added per well in 60 wells of a 96-well plate.
Cells were differentiated according to the ZenBio-proto-
col. On the 11th day from the start of differentiation
(before the peak of adiponectin secretion), dexametha-
sone was removed from the medium. 24 hours later, the
cells were subjected to treatments as follows: medium
only, 100 nM cortisone, 0.1 µM BVT116429 + 100 nM
cortisone, 10 µM BVT116429 + 100 nM cortisone. Cells
were exposed for 48 hours where after the medium was
transferred to a fresh 96-well plate and stored at -20°C
until analyzed. The adiponectin levels were analyzed with
a human adiponectin ELISA kit (CYT350, Chemicon Int.)
according to the manufacturer's instructions.
Statistical analysis
Data are expressed as means ± SE. Results were subjected
to a one-way ANOVA followed by Dunett's multiple com-
parison test, or the nonparametric Kruskal-Wallis test fol-
lowed by Dunn's test. Prism 4 for windows (GraphPad
software Inc) was used for statistical analysis.
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